Siga Technologies
SIGA Technologies Inc is an American commercial-stage pharmaceutical company specializing in health security and antiviral countermeasures for orthopoxviruses including smallpox, mpox, and cowpox. The company commercializes TPOXX (tecovirimat), an FDA-approved antiviral treatment available in oral and intravenous formulations, stockpiled by government biodefense agencies globally. Principal revenues derive from government procurement contracts for biodefense stockpiling, notably with the US Strategic National Stockpile (BARDA) and international health ministries. Core end markets encompass national defense agencies, public health ministries, biodefense stockpiling programs, and emergency medical responders across the United States, Canada, Europe, and international allies. SIGA Technologies holds a market-leading position globally as the primary developer and supplier of targeted smallpox and orthopoxvirus antiviral therapeutics. The corporation is headquartered in New York, New York, and its common stock trades on the Nasdaq Global Market.
2 of the funds FundTelligence covers report a position in Siga Technologies.
- Legal name
- SIGA TECHNOLOGIES INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Siga Technologies
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.09 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)